Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.44 |
| ▸ | NPC1 | O15118 | 10/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2296479 | 0.93 | NPC1 (0.39) | RAB9ANPC1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL2295353 | 0.92 | RAB9A (0.45) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL2296510 | 0.91 | TMPRSS4 (0.50) | RAB9ANPC1SMN1; SMN2LMNATP53 | |
| SCHEMBL2296222 | 0.91 | RAB9A (0.42) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL2295278 | 0.87 | MEN1 (0.45) | RAB9ANPC1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL2292725 | 0.87 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL2295816 | 0.86 | RAB9A (0.45) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL2297464 | 0.86 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL2295674 | 0.86 | NPC1 (0.56) | RAB9ANPC1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL5292979 | 0.86 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | RAB9A 1893/4885NPC1 2770/4885SMN1; SMN2 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.